Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deudomperidone - CinRx Pharma

Next Previous
Search
Drug Profile

Deudomperidone - CinRx Pharma

Alternative Names: CIN-102; Deuterated domperidone; Domperidone deuterated - CinRx Pharma

Latest Information Update: 01 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CinRx Pharma
  • Developer CinDome Pharma
  • Class Antiemetics; Benzimidazoles; Chlorinated hydrocarbons; Gastrokinetics; Organic deuterium compounds; Piperidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastroparesis

Most Recent Events

  • 28 Mar 2025 CinDome Pharma plans a phase II trial for Gastroparesis in March 2025 (PO) (NCT06899217)
  • 08 May 2023 Efficacy data from the phase I trial in Healthy volunteers presented at the Digestive Disease Week 2023 (DDW-2023)
  • 27 Mar 2023 CinDome Pharma initiates phase II envision3D trial for Diabetic gastroparesis in the USA (NCT05832151)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top